Vikram Verghese Sells 6,640 Shares of Heartflow (NASDAQ:HTFL) Stock

Heartflow, Inc. (NASDAQ:HTFL) CFO Vikram Verghese sold 6,640 shares of Heartflow stock in a transaction that occurred on Tuesday, September 8th. The shares were sold at an average price of $50.03, for a total transaction of $332,199.20. Following the sale, the chief financial officer directly owned 214,503 shares in the company, valued at $10,731,585.09. This trade represents a 3.00% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Vikram Verghese also recently made the following trade(s):

• On Thursday, September 3rd, Vikram Verghese sold 27,540 shares of Heartflow stock. The shares were sold at an average price of $49.69, for a total transaction of $1,368,462.60.
• On Wednesday, September 2nd, Vikram Verghese sold 5,876 shares of Heartflow stock. The shares were sold at an average price of $50.60, for a total transaction of $297,325.60.

Heartflow Stock Down 2.5%

Shares of NASDAQ HTFL traded down $1.18 during midday trading on Thursday, reaching $45.49. 2,256,650 shares of the company were exchanged, compared to its average volume of 1,550,843. The stock’s 50-day moving average price is $34.73 and its 200-day moving average price is $30.50. The stock has a market cap of $3.96 billion and a P/E ratio of -24.86. Heartflow, Inc. has a one year low of $20.13 and a one year high of $51.78.

Heartflow (NASDAQ:HTFL) last announced its quarterly earnings results on Thursday, August 13th. The company reported ($0.07) EPS for the quarter, beating analysts’ consensus estimates of ($0.22) by $0.15. The company had revenue of $64.08 million during the quarter. Heartflow had a negative return on equity of 23.52% and a negative net margin of 55.82%.The company’s revenue for the quarter was up 47.7% on a year-over-year basis. On average, equities research analysts anticipate that Heartflow, Inc. will post -0.75 EPS for the current year.

Analyst Upgrades and Downgrades

HTFL has been the subject of several recent research reports. Freedom Capital raised Heartflow to a “strong-buy” rating in a research note on Tuesday, June 30th. Robert W. Baird set a $45.00 price target on shares of Heartflow in a research report on Friday, August 14th. Benchmark reaffirmed a “buy” rating on shares of Heartflow in a research note on Friday, August 14th. Stifel Nicolaus lifted their price target on shares of Heartflow from $40.00 to $45.00 and gave the stock a “buy” rating in a report on Friday, August 14th. Finally, UBS Group started coverage on shares of Heartflow in a research note on Wednesday. They issued a “neutral” rating and a $55.00 price objective on the stock. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $44.88.

Hedge Funds Weigh In On Heartflow

A number of institutional investors and hedge funds have recently modified their holdings of the business. Vanguard Group Inc. bought a new stake in shares of Heartflow in the 3rd quarter valued at $48,871,000. Legal & General Group Plc acquired a new stake in Heartflow in the third quarter worth $59,000. Franklin Resources Inc. acquired a new stake in Heartflow in the third quarter worth $10,829,000. UBS Group AG bought a new stake in Heartflow in the third quarter valued at $5,130,000. Finally, Sei Investments Co. acquired a new position in shares of Heartflow during the third quarter valued at about $303,000.

Heartflow Company Profile

HeartFlow, Inc (NASDAQ: HTFL) is a medical technology company that develops non-invasive diagnostic solutions for coronary artery disease. The company’s core offering translates coronary CT angiography (CTA) data into a patient-specific, three-dimensional physiological model of the coronary arteries. Using advanced image processing and computational modeling, HeartFlow’s analysis estimates fractional flow reserve (FFR) values throughout the coronary tree to identify ischemia-producing lesions without the need for invasive pressure-wire measurements.

HeartFlow’s cloud-based service integrates with clinical workflows: clinicians submit coronary CTA images and receive a detailed, color-coded 3D map and report that highlights lesion-specific FFR values and physiological impact.